Document is current
Any future updates will be listed below
-
Authors
Lyckenvik, Tim
Olsson, Martin
Forsberg, My
Wasling, Pontus
Zetterberg, Henrik
Hedner, Jan
Hanse, Eric
-
Funding
Funding for this research was provided by:
University of Gothenburg
- License Information
-
More Information
Article History
Received: 4 June 2025
Accepted: 12 August 2025
First Online: 19 August 2025
Declarations
:
: This study was approved by the Swedish Ethical Review Authority in Gothenburg (Regionala etikprövningsnämnden i Göteborg), protocol number #492 − 18. Each participant gave oral and written informed consent to participate in the study before inclusion. The study was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche; and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
